Health TrialsbyHealthPanel

Prevelance of Axial Spondylosis Arthritis in Inflammatory Bowel Disease and Its RESPONSE to Tumour Necrosis Factor (TNF) Inhibitors Treatment in Assiut University Hospital

ConditionsInflammatory Bowel Disease (IBD)SpondylarthropathiesTNF-alpha Inhibitors
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-60
SponsorMohamed Nasr

About this trial

Prevelance of axial spondylosis arthritis in inflammatory bowel disease and its RESPONSE to tumour necrosis factor (TNF) inhibitors TREATMENT

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial population

IBD patients (ulcerative colitis , Crohs disease ) in gastroenterology department ,ASSUIT UNIVERSITY hospital and EL RAGHY hospital inpatient and outpatient clinics

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • TNF inhibitors

    Drug

    tumour necrosis factor inhibitors approved as treatments for ulcerative colitis and/or Crohns disease

  • conventional ibd medical treatment

    Drug

    Conventional therapies for ulcerative colitis and Crohns disease (CD) include aminosalicylates, corticosteroids, thiopurines, methotrexate other than anti-tumor necrosis factor agents.

Treatment groups

100 Participants
are divided into 2 treatment groups
Group A: (TNF) inhibitors1 intervention
Group B: conventional IBD medical Treatment1 intervention

Trial outcomes

Primary outcomes

1

prevalence of SPA in IBD patients

Time frame
baseline

Secondary outcomes

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Mohamed Nasr

Lead sponsor

Assiut University

Sponsor institution

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: